Last reviewed · How we verify
OPUVIZ (AFLIBERCEPT-YSZY)
OPUVIZ (generic name: AFLIBERCEPT-YSZY) is a drug developed by SAMSUNG BIOEPIS CO LTD. It is currently FDA-approved.
OPUVIZ is a protein-based inhibitor of vascular endothelial growth factor A, long form. It is classified as a vascular endothelial growth factor A inhibitor.
At a glance
| Generic name | AFLIBERCEPT-YSZY |
|---|---|
| Sponsor | SAMSUNG BIOEPIS CO LTD |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- OPUVIZ CI brief — competitive landscape report
- OPUVIZ updates RSS · CI watch RSS
- SAMSUNG BIOEPIS CO LTD portfolio CI
Frequently asked questions about OPUVIZ
What is OPUVIZ?
OPUVIZ (AFLIBERCEPT-YSZY) is a pharmaceutical drug developed by SAMSUNG BIOEPIS CO LTD.
Who makes OPUVIZ?
OPUVIZ is developed and marketed by SAMSUNG BIOEPIS CO LTD (see full SAMSUNG BIOEPIS CO LTD pipeline at /company/samsung-bioepis).
What is the generic name of OPUVIZ?
AFLIBERCEPT-YSZY is the generic (nonproprietary) name of OPUVIZ.
What development phase is OPUVIZ in?
OPUVIZ is FDA-approved (marketed).
Related
- Manufacturer: SAMSUNG BIOEPIS CO LTD — full pipeline
- Therapeutic area: All drugs in Other
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing